145 related articles for article (PubMed ID: 12192595)
1. Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma.
van Golen KL; Bao L; Brewer GJ; Pienta KJ; Kamradt JM; Livant DL; Merajver SD
Neoplasia; 2002; 4(5):373-9. PubMed ID: 12192595
[TBL] [Abstract][Full Text] [Related]
2. Increased potency of the PHSCN dendrimer as an inhibitor of human prostate cancer cell invasion, extravasation, and lung colony formation.
Yao H; Veine DM; Zeng ZZ; Fay KS; Staszewski ED; Livant DL
Clin Exp Metastasis; 2010 Mar; 27(3):173-84. PubMed ID: 20339907
[TBL] [Abstract][Full Text] [Related]
3. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma.
Livant DL; Brabec RK; Pienta KJ; Allen DL; Kurachi K; Markwart S; Upadhyaya A
Cancer Res; 2000 Jan; 60(2):309-20. PubMed ID: 10667582
[TBL] [Abstract][Full Text] [Related]
4. The PHSCN dendrimer as a more potent inhibitor of human breast cancer cell invasion, extravasation, and lung colony formation.
Yao H; Veine DM; Fay KS; Staszewski ED; Zeng ZZ; Livant DL
Breast Cancer Res Treat; 2011 Jan; 125(2):363-75. PubMed ID: 20300829
[TBL] [Abstract][Full Text] [Related]
5. A D-amino acid containing peptide as a potent, noncovalent inhibitor of α5β1 integrin in human prostate cancer invasion and lung colonization.
Veine DM; Yao H; Stafford DR; Fay KS; Livant DL
Clin Exp Metastasis; 2014 Apr; 31(4):379-93. PubMed ID: 24464034
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy and antiangiogenic TM in lung cancer.
Khan MK; Miller MW; Taylor J; Gill NK; Dick RD; Van Golen K; Brewer GJ; Merajver SD
Neoplasia; 2002; 4(2):164-70. PubMed ID: 11896571
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic inhibition of breast cancer bone metastasis progression and lung colonization: breaking the vicious cycle by targeting α5β1 integrin.
Yao H; Veine DM; Livant DL
Breast Cancer Res Treat; 2016 Jun; 157(3):489-501. PubMed ID: 27255534
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer.
Henry NL; Dunn R; Merjaver S; Pan Q; Pienta KJ; Brewer G; Smith DC
Oncology; 2006; 71(3-4):168-75. PubMed ID: 17641535
[TBL] [Abstract][Full Text] [Related]
9. Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer.
Hassouneh B; Islam M; Nagel T; Pan Q; Merajver SD; Teknos TN
Mol Cancer Ther; 2007 Mar; 6(3):1039-45. PubMed ID: 17363496
[TBL] [Abstract][Full Text] [Related]
10. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.
Pan Q; Kleer CG; van Golen KL; Irani J; Bottema KM; Bias C; De Carvalho M; Mesri EA; Robins DM; Dick RD; Brewer GJ; Merajver SD
Cancer Res; 2002 Sep; 62(17):4854-9. PubMed ID: 12208730
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
12. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity.
London CA; Sekhon HS; Arora V; Stein DA; Iversen PL; Devi GR
Cancer Gene Ther; 2003 Nov; 10(11):823-32. PubMed ID: 14605668
[TBL] [Abstract][Full Text] [Related]
13. Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.
Chan N; Willis A; Kornhauser N; Ward MM; Lee SB; Nackos E; Seo BR; Chuang E; Cigler T; Moore A; Donovan D; Vallee Cobham M; Fitzpatrick V; Schneider S; Wiener A; Guillaume-Abraham J; Aljom E; Zelkowitz R; Warren JD; Lane ME; Fischbach C; Mittal V; Vahdat L
Clin Cancer Res; 2017 Feb; 23(3):666-676. PubMed ID: 27769988
[TBL] [Abstract][Full Text] [Related]
14. Copper deficiency as an anti-cancer strategy.
Goodman VL; Brewer GJ; Merajver SD
Endocr Relat Cancer; 2004 Jun; 11(2):255-63. PubMed ID: 15163301
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth.
Doñate F; Parry GC; Shaked Y; Hensley H; Guan X; Beck I; Tel-Tsur Z; Plunkett ML; Manuia M; Shaw DE; Kerbel RS; Mazar AP
Clin Cancer Res; 2008 Apr; 14(7):2137-44. PubMed ID: 18381955
[TBL] [Abstract][Full Text] [Related]
16. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Montico F; Kido LA; Hetzl AC; Cagnon VH
Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
[TBL] [Abstract][Full Text] [Related]
17. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade.
Pan Q; Bao LW; Merajver SD
Mol Cancer Res; 2003 Aug; 1(10):701-6. PubMed ID: 12939395
[TBL] [Abstract][Full Text] [Related]
18. Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy.
Jin F; Xie Z; Kuo CJ; Chung LW; Hsieh CL
Cancer Gene Ther; 2005 Mar; 12(3):257-67. PubMed ID: 15565180
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
Karashima T; Sweeney P; Slaton JW; Kim SJ; Kedar D; Izawa JI; Fan Z; Pettaway C; Hicklin DJ; Shuin T; Dinney CP
Clin Cancer Res; 2002 May; 8(5):1253-64. PubMed ID: 12006546
[TBL] [Abstract][Full Text] [Related]
20. Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma.
Khan MK; Mamou F; Schipper MJ; May KS; Kwitny A; Warnat A; Bolton B; Nair BM; Kariapper MS; Miller M; Brewer G; Normolle D; Merajver SD; Teknos TN
Arch Otolaryngol Head Neck Surg; 2006 Mar; 132(3):333-8. PubMed ID: 16549755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
